Navigation Links
Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability

A new prospective study suggests that ovarian germ cell tumour patients treated with platinum-based chemotherapy and fertility-sparing surgery may retain their menstrual function and reproductive ability.

The study, published in the Journal of Clinical Oncology, also found that despite having reproductive and sexual concerns, survivors were more likely than their healthy counterparts to be involved in meaningful, positive relationships.

Researchers at The University of Texas M. D. Anderson Cancer Center and the Gynecologic Oncology Group claim that this is the largest and most comprehensive survey of survivors ever conducted.

Lead author of the study, Dr. David Gershenson, says that germ cell tumours, a disease in which malignant cells form in the germ or egg of the ovary, constitute just five percent of all ovarian cancers diagnosed.

He explains that there has been a tremendous amount of interest in fertility because it relates to germ cell tumour survivors. Ovarian germ cell tumours often occur in girls and young women, with the average age of diagnosis occurring in the teenage years.

"Before the 1970s, there was no effective treatment for ovarian germ cell tumour patients and the death rate was extremely high. However, with the introduction of platinum-based combination chemotherapy, there's been a dramatic increase in survival, with cure rates now reaching close to 100 percent.

Simultaneously in the 1970s, gynaecologic oncologists began to realize that fertility-sparing surgery could be performed safely and without compromising a woman's curability," says Dr. Gershenson.

During the study, the researchers surveyed 132 germ cell tumour survivors formally enrolled in M. D. Anderson or Gynecologic Oncology Group clinical trials all over the nation. Each patient received platinum-based combination chemotherapy following surgery. The women were compared to 137 health y women, all acquaintances of the survivors. Both the survivors and the acquaintances filled out questionnaires, and were matched for age, race, and education.

Seventy-one of the 132 survivors had fertility-sparing surgery as part of their treatment. The researchers noted that of the 71 patients who had fertility-sparing surgery, 62 women (87 per cent) were still having menstrual periods and 24 survivors had given birth to 37 babies.

"At the time of the study, the median survivor's age was just 35.5 years - this is a very young cohort of survivors. One can only assume that the women will have, or likely already have had, more children since the study," says Dr. Gershenson.

It was also observed that as compared to the healthy women, germ cell tumour survivors had significantly greater reproductive concerns and experienced less sexual pleasure and more sexual discomfort, although the survivors were more likely to be in partnered, meaningful relationships.

"The finding should allow oncologists and therapists to better inform and counsel patients and their families about expectations in the perioperative period, during primary treatment and long term. Ultimately as a cancer community, we need to develop better interventions and pay much more attention to both the psycho-social and fertility issues of our patients," says Dr. Gershenson.

He also stressed the importance of having fertility-sparing surgery performed by a board-certified gynaecological oncologist who understands the clinical behaviour of ovarian germ cell tumours, and who is trained to optimise patients' probability of undergoing appropriate surgery and chemotherapy.

"Still in 2007, despite medical advances, too many of these patients are operated on by general obstetricians and gynaecologists or general surgeons who do not make a proper diagnosis during surgery, or may not truly understand the biology of this disease. As a r esult, both ovaries and the uterus are removed, leaving a patient unnecessarily sterile," he said.


'"/>




Related medicine news :

1. Breast Cancer Survivors Worry About Infertility
2. Breast Cancer Survivors Worry About Infertility
3. An Incentive For Breast Cancer Survivors
4. Better Care Required for Breast Cancer Survivors
5. Exercising Good For Stroke Survivors
6. Tsunami Survivors Face Pneumonia Threat
7. Survivors of childhood cancer may have long-term health problems
8. Encephalitis Survivors Face The Risk Of Becoming Disabled
9. Socialization A Serious Trouble For Childhood Cancer Survivors
10. Pakistani Quake Survivors Face Outbreak Of Diarrhea
11. Chronic Post-Traumatic Stress Disorder (PTSD) Risk In Young Natural Disaster Survivors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent ... health departments have been awarded five-year accreditation status through the Public Health ... being served by a PHAB-accredited health department now extend to more than ...
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
(Date:9/21/2017)... Fort Payne, AL (PRWEB) , ... September 21, ... ... financial preparation provider with offices serving communities in northern Alabama and Georgia, is ... positive breast cancer prevention by utilizing modern early detection methods. , US ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... exhibitors at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, ... together more than 40 speakers — representing such thought-leading companies as JP ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
Breaking Medicine Technology: